Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Goodwill & Intangibles (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Goodwill & Intangibles for 13 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Goodwill & Intangibles changed 0.0% to $1.5 million in Q4 2025 year-over-year; TTM through Oct 2025 was $1.5 million, a 0.0% change, with the full-year FY2025 number at $1.5 million, changed 0.0% from a year prior.
  • Goodwill & Intangibles was $1.5 million for Q4 2025 at PharmaCyte Biotech, roughly flat from $1.5 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $3.5 million in Q1 2021 to a low of $1.5 million in Q2 2024.
  • A 5-year average of $2.8 million and a median of $3.5 million in 2021 define the central range for Goodwill & Intangibles.
  • Peak YoY movement for Goodwill & Intangibles: changed 0.0% in 2021, then tumbled 56.35% in 2024.
  • PharmaCyte Biotech's Goodwill & Intangibles stood at $3.5 million in 2021, then changed by 0.0% to $3.5 million in 2022, then changed by 0.0% to $3.5 million in 2023, then crashed by 56.35% to $1.5 million in 2024, then changed by 0.0% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Goodwill & Intangibles are $1.5 million (Q4 2025), $1.5 million (Q3 2025), and $1.5 million (Q2 2025).